Reach Us +1-217-403-9671
Molecular Drug Targets For Development Of Antidepressant Drugs | 8392
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Molecular drug targets for development of antidepressant drugs

International Conference & Exhibition Bioequivalence and Bioavailability

Dinesh Dhingra

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.1000001

D epression is a heterogeneous mood disorder. The main causes of depression are decreased brain levels of monoamines like noradrenaline, dopamine and serotonin. Therefore, drugs restoring the reduced levels of these monoamines in the brain either by inhibiting monoamine oxidase A or by inhibiting reuptake of these neurotransmitters have been reported to possess antidepressant property. The various other molecular targets for development of antidepressant drugs include nicotinic acetylcholine receptors, glutamate, GABAB, benzodiazepine receptors, neuropeptide Y, neurokinins, corticotropin-releasing factor, neurosteroids, brain- derived neurotrophic factor and cytokines. The relation between nicotine and depression is supported by the fact that transdermal nicotine can improve the mood of depressed patients. Anterior cingulate glutamatergic concentration is found to be significantly decreased in patients of major depression. GABAB receptor antagonism may serve as a basis for the generation of novel antidepressants. Patients on antidepressant drug therapy had decreased serum levels of substance P, thus indicating high levels of substance P in depressed patients. Selective antagonists of the neurokinin NK1, NK2 and NK3 receptors showed antidepressant-like effects. There are a number of studies indicating a hyperactive hypothalamic-pituitary adrenal axis in depressed patients. There is significant elevation of corticotropin- releasing factor concentration in cerebrospinal fluid of patients with major depression. Neurosteroids, particularly allopregnanolone and dehydroepiandrosterone showed antidepressant-like effects. Serum levels of brain-derived neurotrophic factor are decreased in patients of major depression. Alterations in the levels of circulating cytokines such as interleukin 1-beta, interleukin-6, tumor necrosis factor-alpha and interferon-gamma have been linked to a depression.
Relevant Topics